Clean technology leader BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert shared an open letter with stockholders reflecting on 2025 and looking forward to the company's part in "what may be one of the largest infrastructure and technology investment cycles in history."
"Global investment trends driven by artificial intelligence, data centers, electrification, energy storage, and environmental remediation are placing increasing demands on water systems, energy infrastructure, and regulatory compliance," Calvert noted. "BioLargo's portfolio of enabling technologies has been developed to address these challenges at the system level, where performance, sustainability, and economics increasingly converge."
Throughout 2025, BioLargo made progress on multiple technology platforms through ongoing development, validation, and initial deployment efforts, Calvert noted. Management deliberately prioritized strategic advancement over hasty expansion, understanding that rapid growth is most effective when backed by a solid technical and commercial base. This emphasis on capital efficiency and technical precision is intended to facilitate faster, lower-risk scaling as market adoption grows.
"This approach reflects BioLargo's long-standing strategy to develop high-impact technologies patiently, validate them thoroughly, and position them to serve large and growing markets where demand is driven by structural forces rather than short-term trends," Calvert said.
In 2025, BioLargo advanced several projects in New Jersey that demonstrate the company's shift from development to real-world application, according to the letter. First, these projects include the installation of the company's proprietary Aqueous Electrostatic Concentrator (AEC) at a municipal water treatment facility in Lake Stockholm, New Jersey. The AEC offers rapid, effective, and affordable concentration and removal of per- and polyfluoroalkyl substances (PFAS) from water.
The company is also working to formalize a budding public-private partnership that could lead to the construction and operation of one or more Cellinity battery factories aligned with state and regional infrastructure priorities, the letter said.
Finally, Clyra Medical has made significant capital investments with its contract manufacturing partner in the region to expand operational capacity for Clyra's anticipated launch of its medical device products, expected in 2026.
"While these initiatives remain subject to further development and execution, they represent tangible progress toward deployment and reflect growing institutional engagement with BioLargo's technologies," Calvert wrote. "It is also worth noting that BioLargo's engineering team has a long and successful history of working with industry and governments in the State of New Jersey."
Alignment with a Historic Investment Cycle
BioLargo's energy and environmental technologies are increasingly aligned with the needs of industries at the heart of global capital investment, the CEO noted. Data centers and advanced manufacturing facilities face growing constraints related to water use, emissions, energy efficiency, and regulatory compliance. Energy storage systems like lithium-ion are increasingly opposed in local communities due to safety concerns and environmental impact.
"BioLargo's energy and environmental solution — Cellinity® — is designed to support more efficient, sustainable, safe, and compliant system-level performance as scale and regulatory requirements increase," the letter said. "At the same time, BioLargo ushers in a domestic production alternative just as global and domestic priorities are increasingly focused on reducing and reshaping geopolitical supply-chain constraints that affect the energy and energy-storage industries."
In 2025, Clyra Medical Technologies continued to advance through coordinated commercial, product development, and clinical engagement activities, according to the company. What began as a research-intensive effort to evolve BioLargo's proprietary iodine-based technology into groundbreaking medical products has matured into a commercial-stage platform supported by multiple development and market-entry initiatives.
Clyra recently completed its first production run for the non-surgical wound irrigation solution ViaClyr, with medical products distributor Advanced Solution under contract and preparing for market entry, Calvert said. Additionally, Clyra's surgical products are targeted for commercial launch soon after. In parallel, expanded product designs are under development to support additional clinical and commercial applications like dental, wound dressings, and more.
Clinical work is also underway by some of Clyra's key opinion leaders (KOLs), providing real-world application experience and evidence that will help medical professionals understand the safety and efficacy of the products as they seek the best and newest treatment alternatives for their patients, the letter said. Clyra's KOLs will present clinical findings at medical symposiums in early 2026, subject to customary clinical, regulatory, and publication considerations.
"Based on current progress, BioLargo believes 2026 has the potential to represent a period of meaningful revenue contribution from Clyra as well as clinical and market validation of Clyra's products and BioLargo's technologies," Calvert wrote. "Management views this as an important milestone in the platform's evolution from development into active commercialization."
Looking Ahead
As BioLargo moves into 2026, global priorities concerning infrastructure growth, energy storage, environmental cleanup, and medical advancements for human health continue to progress and transform, Calvert said. With several technology platforms maturing and nearing readiness for commercial adoption, along with early deployment initiatives advancing, the company believes it is increasingly in sync with these global priorities and will be well-positioned to attract global attention and commercial success.
"While the timing and scale of market adoption is always uncertain, BioLargo remains focused on executing its strategy and advancing its technologies responsibly," he wrote. "In management's view, the company enters the next phase of its development with the right technologies, the right teams, a disciplined strategy, and timing that is increasingly aligned with years of preparation."
Expert 'Hot' On Company's Long-Term Prospects
Chris Temple from The National Investor shared his thoughts on the company following a recent announcement regarding the AEC's performance, stating, "BioLargo announced that its regimen to remove PFAS 'forever chemicals' from water is even more robust."
Temple also revealed his intention to visit the energy division in Oak Ridge, Tennessee, where the company is working on its new battery technology. "I've been very hot on the long-term prospects of this company, notwithstanding the reality that pitfalls here and there have kept BioLargo's share price somewhat hobbled," Temple remarked during an online interview with Calvert and Steve Harrison, President of BioLargo subsidiary Clyra Medical Technologies, on November 20. "We've seen a couple of times in the last year or so some rallies and then setbacks."
Moreover, Richard Ryan, an analyst with Oak Ridge Financial, has pointed out, "The large emerging market for PFAS removal and BLGO's growing validation in this opportunity should not be overlooked." Ryan reiterated his Buy rating on the stock on November 19.
The Catalysts: Multiple Shots on Goal for Co.
The PFAS filtration industry is anticipated to expand from US$2.13 billion in 2025 to US$2.99 billion by 2030, with a compound annual growth rate (CAGR) of 7% over this period, according to a report by Markets and Markets. This expansion is primarily fueled by growing awareness of the severe health and environmental dangers posed by PFAS. These chemicals are extremely persistent and have been associated with cancer, hormone disruption, immune system effects, and other chronic health problems. As a result, governments around the world, especially in North America, Europe, and parts of Asia, are enforcing stricter regulations on PFAS levels in drinking water, industrial wastewater, and consumer products. These regulatory actions are encouraging municipalities and industries to invest in technologies that can effectively remove PFAS. The main factors driving market growth include rising health and environmental concerns, tougher environmental regulations, and an increasing demand for clean and safe drinking water.
According to Grand View Research, regulatory agencies such as the U.S. Environmental Protection Agency (EPA) and the European Chemicals Agency (ECHA) are imposing stricter limits on PFAS concentrations in drinking water, compelling municipalities and industries to adopt advanced treatment technologies. Increased investments in wastewater infrastructure, along with technological advancements in adsorption, membrane filtration, and destruction processes, are boosting market adoption across industrial, commercial, and municipal sectors.
"The market presents significant growth opportunities driven by increasing investments in advanced remediation technologies and the emergence of sustainable treatment materials," Grand View stated. "The rising focus on green chemistry and circular economy principles is fostering the development of eco-friendly adsorbents, regenerable resins, and PFAS destruction methods such as plasma and electrochemical oxidation."
The worldwide demand for grid-scale energy storage is swiftly increasing to meet rising needs. In 2024, the U.S. Energy Information Administration (EIA) reported a 66% increase in battery energy storage capacity within the United States. Although lithium-ion batteries currently dominate this field, they pose several challenges, including fire hazards due to thermal runaway, efficiency degradation over time, and sourcing challenges related to rare and critical minerals. BioLargo stated that its Cellinity battery technology addresses these issues by utilizing innovative materials and designs to provide superior thermal performance and operational efficiency without depending on rare earth elements. According to a February report by the International Energy Agency (IEA), global electricity consumption is projected to grow at its fastest pace in recent years, increasing by nearly 4% annually through 2027 as power usage rises across various sectors.
Streetwise Ownership Overview*According to Future Market Insights, the worldwide market for anti-biofilm wound dressings is expected to expand at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2035, reaching US$2.4 billion from US$943.5 million. This growth is mainly driven by the rising occurrence of surgical site infections, diabetic ulcers, and chronic wounds. Biofilms, which contribute to antibiotic resistance and delayed healing, are also a significant concern. In the United States, the market is anticipated to grow substantially, with a projected CAGR of 9.3% during the forecast period. This expansion is driven by the prevalence of chronic wounds, an aging population, the demand for advanced care, technological advancements, and government initiatives, according to the research firm.
Ownership and Share Structure1
About 13.79% of BioLargo is owned by insiders and management. They include Chief Science Officer Kenneth Code with 8.17%, CEO Calvert with 3.3%, and Director Jack Strommen with 1.56%.
About 0.04% is held by the institution First American Trust. The rest, 86%, is retail.
Its market cap is US$54.97 million, with about 313.76 million shares outstanding and about 270.51 million free-floating. It trades in a 52-week range of US$0.32 and US$0.14.
| Want to be the first to know about interesting Technology, Biotechnology / Pharmaceuticals, Special Situations and Clean Energy investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
- Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
